A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.

A Phase-IIIb Individually Randomized, Placebo-controlled Trial on Safety of RSVA/B-preF Vaccine in Pregnant Women and Efficacy Against Severe RSV-associated Lower Respiratory Tract Infection in Infants

Respiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too early and those born with heart and lung problems. It is the most common cause for children under 5 years old to be hospitalised. In 2019, there were about 33 million RSV-infections in the lower respiratory tract (in the lungs and below the voice box) of which 3,6 million people were hospitalised and 26,300 passed away in hospital due to RSV. Almost half (50%) of deaths that are caused by RSV, happen in children younger than 6 months old and the majority (more than 95%) of these deaths happen to infants and children in low- and middle-income countries.

A way that can help protect babies from becoming infected is through giving vaccines against the germ (RSV) that is targeted for prevention. There are currently no registered vaccines that can be given directly to babies however there is a lot of information available that shows that a vaccine can be safely giving to a mother while she is still pregnant. The mother then produces antibodies (protection cells) that is transferred to the baby before the baby is born, and the baby is protected from getting sick during the first few months of life.

One of the vaccines that has been developed (ABRYSVO) has been used in many clinical trials in pregnant moms (and older people) to test if it is safe and will protect young babies and much older people who are all at the highest risk for a severe RSV disease. The vaccine was given to more than 4,000 pregnant women. The results from the study and previous studies showed that the vaccine was safe and the babies had a lower chance of getting severe RSV disease and going to hospital. It showed that the vaccine prevented severe RSV infection in around 80% of babies younger than 90 days, and 70% of babies younger than 6 months. Therefore, the vaccine has been licensed in a few countries around the world (including the United States of America and other high-income countries) which means that pregnant women can receive this vaccine during their pregnancy if they wish to (without being on a clinical trial). It has also been licensed in South Africa but is not yet available in the country for pregnant women to receive. The licensure is also underway in other African countries.

However, the results of the previous studies of this vaccine also showed that a slightly higher number of premature babies were born to women who received the vaccine compared to women who did not receive the vaccine. The information received from these studies was however not enough to decide if the earlier births were related to the vaccine or not, and more information is needed - which is one of the main reasons for this study. Importantly, all of the babies who were born earlier were only born a few weeks earlier than expected (around 35 weeks of pregnancy), and all the babies were well and survived. The previous studies on this vaccine happened during the COVID-19 pandemic at which time people were wearing masks and contacting other people less therefore not spreading RSV around as we would normally expect. By doing this study, it will assist the investigators to determine if the vaccine is really as good as it is perceived to be for preventing serious RSV illness in the babies.

This RSV vaccine is a very important medical intervention, and it is as important that the effect that this vaccine will have on pregnant women and on the infants born to mothers who receive the vaccine can be measured. It is especially important in African and lower-middle income countries as the vaccine was not tested as much in people living in Africa compared to others. Therefore, the main reason for doing this trial is to see how much value the vaccine can bring to these countries in terms of protecting young babies and infants where many may get a severe infection and be hospitalised. It will also measure if the vaccine does increase the chances of a baby being born earlier than expected. It will only be carried out in the countries after the vaccine has been approved for use by pregnant women (at the right time) as part of their pregnancy care.

Study Overview

• Status: Recruiting
• Conditions: Preterm Labour; RSV Immunisation; RSV Infections
• Intervention / Treatment: Drug: Vaccine; Other: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 13000
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Lisa Nunes; Phone Number: +27119834283; Email: lisa.nunes@wits-vida.org
• Study Contact Backup: Name: Anthonet Koen; Phone Number: +27119834283; Email: anthonet.koen@wits-vida.org

Study Locations

• Ghana
  • Bono East
    • Kintampo, Bono East, Ghana
      • Not yet recruiting
      • Kintampo Health Research Centre
      • Principal Investigator: Kwaku Poku Asante
      • Contact: Kwaku Poku Asante; Phone Number: +233 20 931 9145; Email: kwakupoku.asante@kintampo-hrc.org
  • Greater Accra Region
    • Dodowa, Greater Accra Region, Ghana
      • Not yet recruiting
      • Dodowa Health Research Centre
      • Contact: George Armah; Phone Number: +233244167999; Email: GArmah@noguchi.ug.edu.gh
      • Principal Investigator: George Armah
• Kenya
  • Kilifi County
    • Kilifi, Kilifi County, Kenya, 230-80108
      • Not yet recruiting
      • Kenya Medical Research Institute Wellcome Trust
      • Contact: Joyce Nyiro; Phone Number: +254724895735; Email: jnyiro@kemri-wellcome.org
      • Principal Investigator: Joyce Nyiro
  • Nyanza
    • Kisumu, Nyanza, Kenya, 40100
      • Recruiting
      • Kenya Medical Research Institute Centre for Global Health Research
      • Contact: Nancy Otieno; Phone Number: (057) 2022983; Email: notieno@kemri.go.ke
      • Principal Investigator: Nancy Otieno
• South Africa
  • Gauteng
    • Hillbrow, Gauteng, South Africa, 2001
      • Recruiting
      • Wits RHI Shandukani CRS
      • Principal Investigator: Lee Fairlie
      • Contact: Lee Fairlie; Email: lfairlie@wrhi.ac.za
    • Johannesburg, Gauteng, South Africa, 2093
      • Recruiting
      • VIDA Nkanyezi Research Unit
      • Contact: Renate Strehlau; Phone Number: +27114709214; Email: renate.strehlau@wits.ac.za
      • Principal Investigator: Renate Strehlau
    • Soshanguve, Gauteng, South Africa, 0152
      • Recruiting
      • Setshaba Research Centre
      • Contact: Patience Kwedza; Phone Number: +27127992422; Email: pkwedza@setshaba.org.za
      • Principal Investigator: Patience Kwedza
    • Soweto, Gauteng, South Africa, 1864
      • Recruiting
      • Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit
      • Contact: Johann Greffrath; Phone Number: +27119834283; Email: johann.greffrath@wits-vida.org
      • Principal Investigator: Johann Greffrath
  • KwaZulu-Natal
    • Durban, KwaZulu-Natal, South Africa, 4052
      • Recruiting
      • Enhancing Care Foundation
      • Principal Investigator: Rosie Mngqibisa
      • Contact: Rosie Mngqibisa; Phone Number: +27312611093; Email: mngqibisa@ecarefoundation.com
  • Western Cape
    • Rondebosch, Western Cape, South Africa, 7700
      • Recruiting
      • MRC Unit on Child And Adolescent Health
      • Contact: Heather Zar; Phone Number: +27216585324; Email: heather.zar@uct.ac.za
      • Principal Investigator: Heather Zar
• The Gambia
  • Upper River Division
    • Basse Santa Su, Upper River Division, The Gambia
      • Recruiting
      • MRC Unit The Gambia at London School of Hygiene & Tropical Medicine
      • Contact: Grant Mackenzie; Phone Number: (+220) (0) 4495835; Email: gmackenzie@mrc.gm
      • Principal Investigator: Grant Mackenzie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Pregnant women considered to be legally competent, as per country legislation, to consent for trial participation for herself and her newborn
• At a gestational age in keeping with in-country approval of the vaccine administration, and not in active labour. Gestational age will be based on GAIA LOC 1 to 2B criteria
• Mother is able to understand and comply with planned trial procedures
• Mother is attending ante-natal clinic
• Mother has documented test for HIV and syphilis during the current pregnancy,
• Provides written informed consent prior to initiation of trial. If the maternal participant is illiterate, a witnessed thumb-printed informed consent is acceptable
• Intention to deliver at a hospital or birthing facility where trial procedures can be obtained (for immunogenicity cohort)
• Expected to be available for the duration of the trial and can be contacted by telephone or by physical visit during trial participation
• Participant is willing to give informed consent for her infant to participate in the trial

Exclusion Criteria:

• Body mass index of >40 kg/m2 at the time of the first obstetric visit during the current pregnancy
• Bleeding diathesis or condition (past or present) associated with prolonged bleeding that would, in the opinion of the investigator, contra-indicate intramuscular injection
• History of severe adverse reaction associated with a vaccine

• Current pregnancy complications or abnormalities at the time of consent that will increase the risk associated with the participation in and completion of the trial, including but not limited to the following:

  1. More than two fetuses (i.e. twins will be allowed)
  2. Preeclampsia, eclampsia, or uncontrolled gestational hypertension
  3. Known placental abnormality.
  4. Known polyhydramnios or oligohydramnios
  5. Known endocrine disorders, including untreated hyperthyroidism or untreated hypothyroidism, or uncontrolled diabetes mellitus at the time of consent.
  6. Any signs of premature labour with the current pregnancy or having ongoing intervention (medical/ surgical) in the current pregnancy to prevent preterm birth.

• At least THREE prior pregnancy complications or abnormalities at the time of consent, based on the investigator's judgment, that will increase the risk associated with the participation in and completion of the trial, including but not limited to the following:

  1. Prior preterm delivery between 18 to ≤34 weeks gestation, or birth weight <2200 grams; (may be based on maternal history of prior preterm delivery where these details are not otherwise documented)
  2. Prior stillbirth or neonatal death within 7 days of birth.
  3. Previous infant with a known genetic disorder or major congenital anomaly
• Mother who is positive for syphilis and untreated at time of enrolment
• Mother living with HIV/AIDS considered to have WHO Clinical Stage 3 or 4 AIDS, or considered to be clinically unstable
• Major illness of the maternal participant or conditions of the foetus that, in the investigator's judgment, will substantially increase the risk associated with the maternal participant's participation in, and completion of, the trial
• Known or history of congenital or acquired immunodeficiency disorder, or rheumatologic disorder or other illness requiring chronic treatment with known immunosuppressant medications, including monoclonal antibodies, within the year prior to enrolment
• Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behaviour or laboratory abnormality that may increase the risk associated with trial participation and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial
• Participation in other studies involving investigational drug(s) within 28 days prior to consent and/or during trial participation.
• Use of systemic corticosteroids for >14 days within 28 days prior to trial enrolment. Prednisone use of <20 mg/day for ≤14 days is permitted. Inhaled/nebulized, intra-articular, intra-bursal, or topical (skin or eyes) corticosteroids are permitted
• Current alcohol abuse or illicit drug use
• Receipt of blood or plasma products or immunoglobulin (Ig) in past 60 days or planned receipt through delivery, with exception of Rho(D) immune globulin (eg, RhoGAM), which can be given at any time
• Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during trial participation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Control group will receive the placebo which will match the vaccine to maintain the blind but will not contain any active product. Participants will be randomised 1:1	Other: Placebo; Placebo matched to vaccine but not containing any active ingredients
Active Comparator: ABRYSVO (RSV A/B-pre-F vaccine); ABRYSVO vaccine developed by Pfizer. The active ingredients in RSVpre-F are 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B, in a lyophilized dosage form for reconstitution	Drug: Vaccine; The active ingredients in RSVpreF are 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B, in a lyophilized dosage form for reconstitution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the efficacy of RSVA/B-preF against RSV-A or RSV-B subtype confirmed severe LRTI through to 180 days of age by measuring the first occurrence of RT-PCR confirmed RSV severe LRTI	The presence of LRTI will be confirmed according to case definition. The severity of LRTI will be based on the WHO grading criteria	From infant birth to 180 days of age
Evaluate the safety of RSVA/B-preF in relation to preterm births in women with gestational age (GA) staging Level of Certainty [LOC] 1 to 2B at time of enrolment by measuring the occurrence of preterm births (<37 weeks GA)	The GA staging will be based on Global Alignment on Immunization safety Assessment (GAIA) criteria	At delivery of the infant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the efficacy of RSVA/B-preF against RSV-confirmed severe LRTI through to 90, 120 and 150 days of age by measuring the first occurrence of RT-PCR confirmed RSVA or RSVB severe LRTI		90, 120 and 150 days of age
Evaluate the efficacy of RSVA/B-preF against RSV-confirmed LRTI resulting in hospitalization with use of supplemental oxygen OR O2 saturation of <92% (at 180 days, 90, 120 & 150 days) by measuring the first occurrence of RT-PCR confirmed RSVA or RSVB		At 90, 120, 150 and 180 days of age
Evaluate the efficacy of RSVA/B-preF against RSV-confirmed MA-LRTI and very-severe LRTI (at 180 days, and 90, 120 and 150 days) by measuring the first occurrence of RT-PCR confirmed RSVA or RSVB MALRTI or very-severe LRTI		90, 120, 150 and 180 days of age
Evaluate the efficacy of RSVA/B-preF against RSV-confirmed: a. MA-LRTI; b. severe-LRTI; c. very-severe LRTI; d. LRTI hospitalization from 0 to 90 days and 91-180 days by measuring the first occurrence of RT-PCR confirmed RSVA or RSVB MA-LRTI		0-90 and 91-180 days of age
Evaluate the efficacy of RSVA/B-preF against all-cause: a. MA-LRTI; b. severe LRTI; c. very-severe LRTI; d. LRTI hospitalization, by measuring the first occurrence of all-cause MALRTI		at 180 days, and 90, 120, and 150 days; and at 0-90 days and 91-180 days of age
Evaluate the safety of RSVA/B-preF against prematurity in women vaccinated at 28 to <32 weeks, 32 to 36 weeks by measuring the occurrence of pre-term delivery (<37 weeks)	Limited to women with GA staging using GAIA LOC 1 to 2B at time of enrolment	At delivery of the infant
Evaluate the safety of RSVA/B-preF against prematurity occurring at 28 to <32 weeks, 32 to 36 weeks by measuring the occurrence of pre-term delivery in the mentioned intervals	Limited to women with GA staging using GAIA LOC 1 to 2B at time of enrolment	At delivery of the infant
Evaluate the safety of RSVA/B-preF against low birth weight (<2500 grams) and very low birth weight (<1500 grams) by measuring the occurrence of low and very low birth weights		At delivery of the infant

Collaborators and Investigators

• Sponsor: University of Witwatersrand, South Africa
• Collaborators: Bill and Melinda Gates Foundation; World Health Organization
• Investigators: Study Chair: Shabir Madhi, Wits Vaccines & Infectious Diseases Analytics Research Unit; Study Director: Ziyaad Dangor, Wits Vaccines & Infectious Diseases Analytics Research Unit

Study record dates

Study Major Dates

• Study Start (Actual): September 3, 2025
• Primary Completion (Estimated): February 29, 2028
• Study Completion (Estimated): February 29, 2028

Study Registration Dates

• First Submitted: April 14, 2025
• First Submitted That Met QC Criteria: April 24, 2025
• First Posted (Actual): May 2, 2025

Study Record Updates

• Last Update Posted (Actual): May 18, 2026
• Last Update Submitted That Met QC Criteria: May 14, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Obstetric Labor Complications; Pregnancy Complications; Infections; RNA Virus Infections; Virus Diseases; Pneumovirus Infections; Paramyxoviridae Infections; Mononegavirales Infections; Respiratory Syncytial Virus Infections; Obstetric Labor, Premature; Biological Products; Complex Mixtures; Vaccines
• Other Study ID Numbers: RSV_IMPACT

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Progress reports for this trial will be made available to the trial funder, ethics committees, regulatory authorities and other stakeholders. Final trial results will be shared with the same stakeholders within 3 months of final lock of the trial database. Study data will be shared with Pfizer in the event of safety concerns or a request from a regulatory agency. Manuscript(s) will be prepared and submitted for peer-review in open access journals. All proposed publications will first be reviewed by Pfizer prior to publication for review of potential confidential information. A publication plan and proposal for criteria of authorship will be established with the sites. The trial database will be made publicly available upon request. Any transfer of data, will be governed, by the terms of the local Ethics Committee (HREC).
• IPD Sharing Time Frame: Within 12 months of availability of study report
• IPD Sharing Access Criteria: Any transfer of data, will be governed, by the terms of the local Ethics Committee (HREC). Data sharing will be done on a collaborative basis, with the site PI (or his nominee) being included in any further interrogation of the data.
• IPD Sharing Supporting Information Type: ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes